Aquablation Therapy

MSLC IS THE FIRST HOSPITAL IN NEW YORK TO OFFER THIS CUTTING EDGE TECHNOLOGY

Montefiore St. Luke’s Cornwall first in New York to offer HYDROS™ Robotic System: A Cutting-Edge AI-Powered Platform for Aquablation Therapy to Treat Benign Prostatic Hyperplasia. This innovative, minimally invasive treatment of benign prostatic hyperplasia (BPH) is an ultrasound-guided, robotic assisted, heat-free waterjet treatment. The HYDROS™ Robotic System will help deliver an accurate and consistent treatment plan for better clinical outcomes.

What is Aquablation Therapy?

Aquablation therapy is a resective procedure, which means that the prostate tissue causing symptoms is surgically removed. No incision is made in the abdomen, as the prostate is reached through the urethra.
Aquablation therapy is performed in a hospital. You will be under anesthesia for the entire procedure. The procedure typically takes an hour and may involve an overnight stay.

How does it work?

Aquablation therapy is the only BPH surgical procedure that combines next-generation ultrasound imaging and digital cystoscopy. With the help of ultrasound imaging, surgeons can create a detailed guide to plan the
procedure, outlining the critical anatomy and suggest an optimal treatment plan for each patient. The tissue within the marked area of the prostate may be removed, while the tissue outside of it may remain untouched.
This real-time visualization allows your surgeon to map which parts of your prostate to remove and which
parts to avoid, specifically enabling surgeons to avoid removing areas that could cause irreversible
complications and would significantly reduce side effects such as erectile dysfunction, ejaculatory dysfunction, and incontinence.

Meet the Provider

Jaspreet Singh, DO
President of MSLC Medical Staff & Urologist